Join the Oncology
Community
Follow Us:  

Melanoma & Skin Cancers

Blog: Melanoma Heads Down the Genetic Pathway

The molecular profiling of melanoma is nigh. Assessment of advanced-stage, metastatic melanoma to determine whether it carries a mutation in the BRAF oncogene will turn routine soon, once physicians have the option to treat these patients with the new BRAF inhibitor drug, vemurafenib.

That might happen any day now. Reuters said on August 9 that the FDA's approval of vemurafenib could be announced soon. Roche/Genentech submitted their NDA for vemurafenib to the FDA in May, and in June came impressive efficacy results in a phase 3 study that was reported at both ASCO and in a NEJM article.

Courtesy Wikimedia Commons/Nephron/Creative Commons License

Histopathology of metastatic melanoma is shown.

 

    

Last week, I covered the American Academy of Dermatology's Summer Academy meeting in New York, where melanoma specialist Richard D. Carvajal from Memorial Sloan-Kettering said that once vemurafenib was on the market genetic analysis of advanced melanomas to find BRAF mutations would suddenly become standard of care. Once testing for one mutation starts, several more genes can easily piggyback onto the assay, which will help to further flesh out the range of genetic mutations that can exist in metastatic melanoma and provide potential targets for new drugs.

It's becoming a well-trodden path that's rapidly driving the treatment of advanced cancers of all kinds into the molecular-profiling era.

Just a couple of weeks ago,

I blogged about how it had already transformed advanced lung cancer management

Continued...
08/10/11


Submitting your vote...
Not rated yet. Be the first who rates this item!
Click the rating bar to rate this item.

> more Melanoma & Skin Cancers articles


Current Issue


The Oncology Report Comprehensive reports and expert commentary on the latest advances in cancer treatment from the world's major oncology meetings.

Past issues, click here »

Calendar
May 8 - 10
Brussels,
Breast International Group (BIG)/ European Society for Medical Oncology (ESMO): IMPAKT Breast Cancer Conference
May 14 - 17
Chicago, IL
American Society of Pediatric Hematology Oncology (ASPHO): Annual Meeting
May 22 - 23
Vienna,
European Musculo-Skeletal Oncology Society (EMSOS): Annual Meeting
May 30 - Jun 3
Chicago, IL
American Society of Clinical Oncology (ASCO): Annual Meeting
Jun 12 - 15
Milan,
European Hematology Association (EHA): Annual Congress
Jun 23 - 24
Paris,
Worldwide Innovative Networking (WIN) Consortium: WIN 2014 Symposium
Jun 25 - 28
Barcelona,
European Society for Medical Oncology (ESMO) Conference: 16th World Congress on Gastrointestinal Cancer
Jun 26 - 27
Milan,
European Institute of Oncology (IEO): 16th Milan Breast Cancer Conference
Jun 26 - 28
Miami, FL
Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium on Supportive Care in Cancer
Jul 5 - 8
Munich,
23rd Biennial Congress of the European Association for Cancer Research
More Calendar »
¢